The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease

Interstitial lung disease (ILD) is the principal cause of death in polymyositis/dermatomyositis (PM/DM). Here we investigated prognostic factors for death and serious infection in PM/DM-ILD using the multicenter database. We retrospectively reviewed baseline demographic, clinical and laboratory find...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis research & therapy 2018-01, Vol.20 (1), p.7-7, Article 7
Hauptverfasser: Sugiyama, Yumiko, Yoshimi, Ryusuke, Tamura, Maasa, Takeno, Mitsuhiro, Kunishita, Yosuke, Kishimoto, Daiga, Yoshioka, Yuji, Kobayashi, Kouji, Takase-Minegishi, Kaoru, Watanabe, Toshiyuki, Hamada, Naoki, Nagai, Hideto, Tsuchida, Naomi, Soejima, Yutaro, Nakano, Hiroto, Kamiyama, Reikou, Uehara, Takeaki, Kirino, Yohei, Sekiguchi, Akiko, Ihata, Atsushi, Ohno, Shigeru, Nagaoka, Shouhei, Nakajima, Hideaki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Interstitial lung disease (ILD) is the principal cause of death in polymyositis/dermatomyositis (PM/DM). Here we investigated prognostic factors for death and serious infection in PM/DM-ILD using the multicenter database. We retrospectively reviewed baseline demographic, clinical and laboratory findings, treatment regimens and outcomes in patients with PM/DM-ILD. The distribution of ILD lesions was evaluated in four divided lung zones of high-resolution computed tomography images. Of 116 patients with PM/DM-ILD, 14 died within 6 months from the diagnosis. As independent risk factors for early death, extended ILD lesions in upper lung fields (odds ratio (OR) 8.01, p = 0.016) and hypocapnia (OR 6.85, p = 0.038) were identified. Serious infection was found in 38 patients, including 11 patients who died of respiratory or multiple infections. The independent risk factors were high serum KL-6 (OR 3.68, p = 0.027), high initial dose of prednisolone (PSL) (OR 4.18, p = 0.013), and combination immunosuppressive therapies (OR 5.51, p 
ISSN:1478-6362
1478-6354
1478-6362
DOI:10.1186/s13075-017-1506-7